These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 21550960)
1. Effect of vitamin D therapy on bone turnover markers in postmenopausal women with osteoporosis and osteopenia. Tanzy ME; Camacho PM Endocr Pract; 2011; 17(6):873-9. PubMed ID: 21550960 [TBL] [Abstract][Full Text] [Related]
2. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. Geller JL; Hu B; Reed S; Mirocha J; Adams JS Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035 [TBL] [Abstract][Full Text] [Related]
3. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. Middleton ET; Steel SA; Aye M; Doherty SM J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000 [TBL] [Abstract][Full Text] [Related]
4. Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial. Jafarnejad S; Djafarian K; Fazeli MR; Yekaninejad MS; Rostamian A; Keshavarz SA J Am Coll Nutr; 2017; 36(7):497-506. PubMed ID: 28628374 [TBL] [Abstract][Full Text] [Related]
5. The Relevance of Osteoclastic and Osteoblastic Activity Markers Follow-Up in Patients on Antiresorptive Osteoporosis Treatment. Smilic TN; Novakovic TR; Markovic-Jovanovic SR; Smilic LLJ; Mitic JS; Radunovic ML J Clin Densitom; 2018; 21(3):322-328. PubMed ID: 29103946 [TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256 [TBL] [Abstract][Full Text] [Related]
7. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment. Iba K; Sonoda T; Takada J; Dohke T; Yamashita T J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388 [TBL] [Abstract][Full Text] [Related]
8. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates. Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579 [TBL] [Abstract][Full Text] [Related]
9. POTASSIUM CITRATE DECREASES BONE RESORPTION IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA: A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL. Gregory NS; Kumar R; Stein EM; Alexander E; Christos P; Bockman RS; Rodman JS Endocr Pract; 2015 Dec; 21(12):1380-6. PubMed ID: 26401577 [TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142 [TBL] [Abstract][Full Text] [Related]
11. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. Deane A; Constancio L; Fogelman I; Hampson G BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897 [TBL] [Abstract][Full Text] [Related]
12. A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial. Elam ML; Johnson SA; Hooshmand S; Feresin RG; Payton ME; Gu J; Arjmandi BH J Med Food; 2015 Mar; 18(3):324-31. PubMed ID: 25314004 [TBL] [Abstract][Full Text] [Related]
13. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women. Yasui T; Miyatani Y; Tomita J; Yamada M; Uemura H; Miura M; Irahara M Gynecol Endocrinol; 2006 Aug; 22(8):455-9. PubMed ID: 17012108 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting. Chiha M; Myers LE; Ball CA; Sinacore JM; Camacho PM Endocr Pract; 2013; 19(6):989-94. PubMed ID: 24013976 [TBL] [Abstract][Full Text] [Related]
15. Vitamin D insufficiency reduces the protective effect of bisphosphonate on ovariectomy-induced bone loss in rats. Mastaglia SR; Pellegrini GG; Mandalunis PM; Gonzales Chaves MM; Friedman SM; Zeni SN Bone; 2006 Oct; 39(4):837-44. PubMed ID: 16765665 [TBL] [Abstract][Full Text] [Related]
16. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT. Bock O; Börst H; Beller G; Armbrecht G; Degner C; Martus P; Roth HJ; Felsenberg D Bone; 2012 Jan; 50(1):317-24. PubMed ID: 22067902 [TBL] [Abstract][Full Text] [Related]
17. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A; Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913 [TBL] [Abstract][Full Text] [Related]
19. Aminohexane bisphosphonate suppresses bone turnover in postmenopausal women more rapidly than oestrogen-gestagen therapy. Tobias JH; Laversuch CJ; Chambers TJ; Gallagher AC Br J Rheumatol; 1996 Jul; 35(7):636-41. PubMed ID: 8670596 [TBL] [Abstract][Full Text] [Related]
20. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women]. Guan YT; Cai LL; Ding HX; Chen GD; Hu Y Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]